We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sharpless, who had been serving as director of the National Cancer Institute, acknowledged that it’s a tough act to follow former Commissioner Scott Gottlieb. Read More
Pennsylvania compounder Summit Health Pharmacy has petitioned the FDA to include oxitriptan on the agency’s 503A bulk substances list—and says the agency should also allow it for compounding in the meantime. Read More
Pfizer is calling on the FDA to retroactively assign four-letter suffixes to biologics that act as reference products for innovative biosimilars. Read More
PhRMA will back “responsible” drug patent reforms, but lawmakers would do well to remember how essential patent protections are to getting life-saving medicines to patients, one of the group’s executives told a Senate panel Tuesday. Read More